TRAVERE THERAPEUTICS, INC. (TVTX) Net margin 2016–2025
TRAVERE THERAPEUTICS, INC. (TVTX) net profit margin by fiscal year — reported net income divided by reported revenue.
-5.2%FY2025 · since FY2016: -35.9% → -5.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -5.2% | +132.7 pp |
| FY2024 | -137.9% | -61.2 pp |
| FY2023 | -76.7% | +177.7 pp |
| FY2022 | -254.4% | -117.8 pp |
| FY2021 | -136.6% | -51.2 pp |
| FY2020 | -85.4% | -1.9 pp |
| FY2019 | -83.5% | -21.0 pp |
| FY2018 | -62.5% | -24.0 pp |
| FY2017 | -38.6% | -2.7 pp |
| FY2016 | -35.9% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More TVTX financial trends
TVTX RevenueTVTX Net incomeTVTX Gross profitTVTX Gross marginTVTX Operating incomeTVTX Operating marginTVTX Operating cash flowTVTX Free cash flowTVTX Capital expendituresTVTX Return on equityTVTX Stock buybacksTVTX Dividends paidTVTX Total assetsTVTX Total liabilitiesTVTX Shareholders’ equityTVTX overview →